ConductScience.org, home

Trial · NCT02637999

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of TherapyMXB Then PEG IFN0Participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of TherapyMXB + PEG IFN Then PEG IFN0Participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of TherapyPEG IFN0Participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of TherapyMXB Then PEG IFN2Participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of TherapyMXB + PEG IFN Then PEG IFN1Participants
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of TherapyPEG IFN3Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of TherapyMXB Then PEG IFN2Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of TherapyMXB + PEG IFN Then PEG IFN6Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of TherapyPEG IFN3Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of TherapyMXB Then PEG IFN1Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of TherapyMXB + PEG IFN Then PEG IFN5Participants
Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of TherapyPEG IFN1Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of TherapyMXB Then PEG IFN4Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of TherapyMXB + PEG IFN Then PEG IFN5Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of TherapyPEG IFN6Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of TherapyMXB Then PEG IFN7Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of TherapyMXB + PEG IFN Then PEG IFN7Participants
Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of TherapyPEG IFN7Participants
Number of Participants With Biochemical Response at Week 12 of TherapyMXB Then PEG IFN2Participants
Number of Participants With Biochemical Response at Week 12 of TherapyMXB + PEG IFN Then PEG IFN2Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02637999/results